Form 4: ADMA Biologics Director Steve Elms Exercises Options and Sells Shares Under Pre-Arranged Plan

ADMA Biologics Director and 10% Owner Steve Elms reported significant stock transactions, including the exercise of multiple stock options and subsequent sales of common stock, all conducted under a Rule 10b5-1 trading plan.

Summary

• Steve Elms, a Director and 10% Owner of ADMA Biologics, Inc., reported multiple transactions involving the company's common stock and stock options.
• On June 13, 2025, Mr. Elms exercised a total of 332,680 stock options with exercise prices ranging from $1.67 to $5.96 per share.
• Following these exercises, Mr. Elms sold a total of 425,621 shares of common stock across three separate transactions between June 12, 2025, and June 16, 2025.
• The sales occurred at weighted average prices of $21.69 (92,941 shares), $20.82 (137,931 shares), and $20.24 (194,749 shares).
• As of June 16, 2025, Mr. Elms directly beneficially owned 87,330 shares of common stock, which includes 10,889 Restricted Stock Units (RSUs) vesting on February 19, 2026.
• Additionally, 2,031,730 shares are indirectly beneficially owned through Aisling Capital II LP, though Mr. Elms disclaims beneficial ownership except for his pecuniary interest.
• All reported transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there are significant sales, they are offset by the exercise of options, indicating profitability for the insider, and the transactions are explicitly stated to be under a Rule 10b5-1 plan, which suggests routine, pre-planned activity rather than a reactive sell-off due to negative company prospects.

Positives

• Exercise of a large number of stock options (332,680 shares) indicates the options were in-the-money and provided a significant gain for the reporting person.
• Continued direct beneficial ownership of 87,330 shares, including 10,889 Restricted Stock Units (RSUs), demonstrates ongoing equity interest in the company.
• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned, non-discretionary sales, which can mitigate concerns about insider selling.

Negatives

• Significant sales of common stock totaling 425,621 shares by a Director and 10% Owner could be perceived negatively by some investors, potentially signaling a reduction in direct exposure to the company's future performance.

Risks

• The vesting of 10,889 Restricted Stock Units (RSUs) on February 19, 2026, is subject to the reporting person's continued service, posing a risk if his service were to terminate before that date.
• The indirect beneficial ownership through Aisling Capital II LP, where Mr. Elms disclaims beneficial ownership except for his pecuniary interest, introduces complexity regarding the ultimate control and disposition of those shares.

Future Outlook

This Form 4 filing details past and current insider transactions and does not provide forward-looking statements or guidance regarding ADMA Biologics, Inc.'s future business performance or financial outlook.

Industry Context

This Form 4 filing reports routine insider trading activity by a director and 10% owner of ADMA Biologics, Inc. Such filings are common across all industries for publicly traded companies and reflect individual compensation and portfolio management decisions rather than broader industry trends or competitive positioning.

Related Party Transactions

• Steve Elms' indirect beneficial ownership of 2,031,730 shares through Aisling Capital II LP, where he is a Managing Member of Aisling Capital Partners, LLC (a control person of Aisling) and a member of the investment committee of Aisling Capital Partners, LP. He disclaims beneficial ownership except for his pecuniary interest.

Stakeholder Impact

• Shareholders: The sale of a significant number of shares by a director and 10% owner, even under a 10b5-1 plan, could be interpreted by some shareholders as a reduction in the insider's direct stake and confidence, although the pre-planned nature mitigates this.

Next Steps

• Vesting of 10,889 Restricted Stock Units (RSUs) on February 19, 2026, subject to Steve Elms' continued service.

Key Dates

Keywords

ADMA Biologics, ADMA, SEC Form 4, Insider Trading, Stock Options, Common Stock, Share Sales, Rule 10b5-1, Director Transactions, Aisling Capital, Restricted Stock Units, Equity Compensation